Current Developments in Antibody Drug Conjugates as Cancer Therapeutics

Dear colleagues,

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small-molecule payloads and two with biological toxins) approved for use by the FDA. This Special Issue aims to give readers a comprehensive understanding of current research in ADC-based cancer therapeutics. The issue aims to publish research work and review articles that detail current advances in each of the ADC components (i.e., monoclonal antibodies, linker moieties and cytotoxic payloads), as well as the ADCs that are at different stages of pre-clinical and clinical evaluation against both solid and liquid tumors. We believe this Special Issue will be of interest to the ADC community, both in industry and academia, and to the early career researchers who are working in the anticancer drug discovery space.

Submissions are welcomed on the following areas:

• Advances in chemistry of cytotoxic payloads;
• Advances in linker development for antibody–drug conjugates;
• Conjugation of payloads with monoclonal antibodies;
• Characterization of antibody–drug conjugates;
• In vitro and in vivo evaluation of antibody–drug conjugates;
• Pre-clinical development of antibody–drug conjugates;
• Clinical evaluation of antibody–drug conjugates;
• Identification of new payloads for antibody–drug conjugates;
• Chemical modification of existing payload classes;
• Identification of new linker types for antibody–drug conjugates, etc.;
• Studies involving new monoclonal antibodies.

Dr. K Miraz Rahman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.